Evidence map›Paper›PMID 27631469›Full record

ReviewDiabetes care2016

Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum.

William T Cefalu, John B Buse, Jaakko Tuomilehto, G Alexander Fleming, Ele Ferrannini, Hertzel C Gerstein, Peter H Bennett, Ambady Ramachandran, Itamar Raz, Julio Rosenstock and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

William T CefaluPennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA.
John B BuseUniversity of North Carolina School of Medicine, Chapel Hill, NC.
Jaakko TuomilehtoChronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; Dasman Diabetes Institute, Dasman, Kuwait; Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia; and Center for Vascular Prevention, Danube University Krems, Krems, Austria.
G Alexander FlemingKinexum, Harpers Ferry, WV.
Ele FerranniniCNR Institute of Clinical Physiology, Pisa, Italy.
Hertzel C GersteinMcMaster University and Hamilton Health Sciences, Hamilton, Canada.
Peter H BennettNational Institutes of Health, Phoenix, AZ.
Ambady RamachandranIndia Diabetes Research Foundation and Dr. A. Ramachandran's Diabetes Hospitals, Chennai, India.
Itamar RazDiabetes Unit, Department of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel.
Julio RosenstockDallas Diabetes and Endocrine Center at Medical City and The University of Texas Southwestern Medical Center, Dallas, TX.
Steven E KahnVA Puget Sound Health Care System and University of Washington, Seattle, WA.

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI JUDD E SHELLITO · 2012 to 2026
$69.1M
Pregnane and Glycosides and Obesity/llya RaskinP50AT002776 · NCCIH · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI RASKIN, ILYA · 2005 to 2019
$24.9M
NCCIH NIH HHS P50 AT002776NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

The International Diabetes Federation estimates that 415 million adults worldwide now have diabetes and 318 million have impaired glucose tolerance. These numbers are expected to increase to 642 million and 482 million, respectively, by 2040. This burgeoning pandemic places an enormous burden on countries worldwide, particularly resource-poor regions. Numerous landmark trials evaluating both intensive lifestyle modification and pharmacological interventions have persuasively demonstrated that type 2 diabetes can be prevented or its onset can be delayed in high-risk individuals with impaired glucose tolerance. However, key challenges remain, including how to scale up such approaches for widespread translation and implementation, how to select appropriately from various interventions and tailor them for different populations and settings, and how to ensure that preventive interventions yield clinically meaningful, cost-effective outcomes. In June 2015, a Diabetes Care Editors' Expert Forum convened to discuss these issues. This article, an outgrowth of the forum, begins with a summary of seminal prevention trials, followed by a discussion of considerations for selecting appropriate populations for intervention and the clinical implications of the various diagnostic criteria for prediabetes. The authors outline knowledge gaps in need of elucidation and explore a possible new avenue for securing regulatory approval of a prevention-related indication for metformin, as well as specific considerations for future pharmacological interventions to delay the onset of type 2 diabetes. They conclude with descriptions of some innovative, pragmatic translational initiatives already under way around the world.

Indexed as

AdultClinical Trials as TopicDiabetes Mellitus, Type 2Glucose IntoleranceHumansHypoglycemic AgentsLife StyleMetforminPrediabetic StateHypoglycemic AgentsMetformin

Identifiers

PMID27631469
PMCPMC4915559

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.